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LITERATURE REVIEW AND RATIONALE
Obesity is a rising epidemic in the United States, 
affecting 35% of adults (body mass index, BMI ≥ 
30 kg/m2), with 4.5% of men and 8% of women being 
severely obese (BMI ≥ 40 kg/m2) (Flegal, Carroll, 
Kit, & Ogden, 2012). It is forecasted that incidence of 
moderate (BMI ≥ 35 kg/m2) and severe obesity will 
continue to increase in the United States (Finkelstein 
et al., 2012). Obesity is a major risk factor for several 
chronic diseases, including diabetes, cardiovascular 
disease, and cancer (WHO, 2016). For those patients 
who wish to lose weight, there are several methods 
that can be used to induce weight loss, including diet, 
exercise, medication, and surgery.
Bariatric surgery is considered to be one of the most 
effective treatments for obesity and is recommended 
for individuals who are moderately or severely obese, 
suffer from an obesity-related health condition, 
and have not responded to other methods of weight 
loss (Jensen et al., 2014; Sjöström et al., 2004). On 
average, a patient’s BMI drops between 8–10 units 
(kg/m2), with maximum weight loss 12 months 
post-surgery (Schauer et al., 2014). Bariatric surgery 
is also very popular; in 2013, 154,276 people with 
severe obesity in the U.S. underwent the procedure 
(Angrisani et al., 2015). 
There are multiple types of bariatric surgery 
procedures. Of those, Roux-en-Y gastric bypass 
(RYGB), seen in Figure 1A, used to be the most 
commonly performed bariatric surgery procedure, 
but is currently declining in popularity (Angrisani et 
al., 2015). In the RYGB surgery, the duodenum of the 
small intestine and most of the stomach is bypassed, 
leaving a 30 mL stomach pouch (MacLean, Rhode, 
& Nohr, 2000). This procedure induces weight loss 
through food restriction and nutrient malabsorption 
(Gletsu-Miller & Wright, 2013). Another type of 
bariatric surgery procedure is the sleeve gastrectomy 
(SG) surgery, seen in Figure 1B, which is currently 
the most popular type of bariatric surgery procedure. 
In this procedure, the surgeon removes a portion 
of the stomach but leaves the intestines intact. This 
induces weight loss through food restriction (Gletsu-
Miller & Wright, 2013).
There are many documented benefi ts of receiving 
bariatric surgery. These benefi ts include resolution 
or improvement of diseases, such as type 2 diabetes, 
cardiometabolic disease, hypertension, depression, 
and reduction in mortality rates (Adams et al., 2012; 
Christou et al., 2004; Dixon et al., 2008; Schowalter 
et al., 2007; Sjöström et al., 2007; Sjöström et 
al., 2012). However, there are also some negative 
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consequence for patients who have had bariatric 
surgery is copper (Cu) defi ciency. Current 
screening methods used for Cu defi ciency are 
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Concentrations of CCS in erythrocytes were 
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for patients supplemented with Fe (p < 0.05). 
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consequences associated with undergoing bariatric 
surgery. Bariatric surgery alters dietary intake and 
nutrient absorption, which may result in nutritional 
defi ciencies following surgery (Gletsu-Miller & Wright, 
2013). Some of the nutritional complications are well-
known and screened for by health care providers, 
including malnutrition of protein, vitamin B12, vitamin 
D, calcium, and iron (Fe). Others that are not typically 
screened for by physicians include B vitamins, fat-
soluble vitamins, and minerals such as copper (Cu) and 
zinc (Clements et al., 2006; Gasteyger, Suter, Gaillard, 
& Giusti, 2008). Without screening, patients who have 
undergone bariatric surgery are at risk for postsurgical 
nutrient defi ciencies that are not being monitored or 
treated appropriately.
As one of the essential minerals, Cu plays many 
important roles in the body by acting as a cofactor 
for the enzyme function of ceruloplasmin (Cp) and 
superoxide dismutase 1 (SOD1) (Homberg & Laurell, 
1947). It also assists in hemoglobin formation, 
cell signaling, and cellular respiration (Fox, 2003; 
Haremaki Fraser, Kuo, Baron, & Weinstein, 2007). 
Dietary Cu requirements are met by most healthy 
adults, because it is found in commonly consumed 
foods such as mushrooms, leafy green vegetables, and 
even cocoa (Trumbo, Yates, Schlicker, & Poos, 2001). 
However, cases of Cu defi ciency have been found as 
a result of bariatric surgery. Cu is absorbed mostly in 
the duodenum of the small intestine, which is bypassed 
in patients who have had the RYGB procedure 
(Mason, 1979). A previous study reported from our 
group determined that incidence of copper defi ciency 
following RYGB surgery was 18.8% (Gletsu-Miller et 
al., 2012). 
One way Cu status can be altered is through 
interactions with Fe. A notable site of interaction 
between Fe and Cu is the divalent metal-ion 
transporter 1 (DMT1), a transporter on the 
basolateral membrane of the enterocyte, where they 
compete for absorption (Gulec & Collins, 2014). In 
addition, both minerals need to be in their reduced 
forms to be absorbed into the enterocyte, thus they 
compete for reduction by cytochrome B reductase 1 
(CYBRD1). Previous studies have shown that high 
dietary Fe results in decreased Cu status in rats 
(Jung-Heun Ha, Zhao, Wang, Flores, & Collins, 
2016). Copper-transporting ATPase 1 (ATP7A) is the 
primary transporter of Cu and is upregulated during 
Fe defi ciency, and is believed to also infl uence Fe 
transport (Collins, Franck, Kowdley, & Ghishan, 
2005). Duodenal epithelial interactions are shown 
in Figure 2 (Guelc & Collins, 2014). One additional 
interaction that should be noted is Cu’s function in 
Fe homeostasis. Cp, a Cu binding molecule, mediates 
Fe release from sites of Fe storage and into the blood 
for Fe to perform essential functions (Hellman & 
Gitlin, 2002).
Currently, there are several methods of assessing 
Cu status. These methods include measuring 
concentrations of erythrocyte SOD1, plasma Cp 
activity, serum Cu, or liver Cu (Danzeisen et al., 
2007). SOD1 has not been found to be a reliable or 
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Figure 1. Depiction of two common bariatric surgery types.
Figure 2. Fe and Cu interaction in the duodenal 
epithelium. Cu and Fe can both be absorbed into the 
enterocyte through DMT1. Additionally, they both 
compete for reduction through CYBRD1. ATP7A is a Cu 
transporter that is upregulated during Fe defi ciency 
(Gulec & Collins, 2014). Copper transporter 1 (Ctrl), trans-
golgi network (TGN), ferroportin 1 (FPN1), hephaestin 
(HEPH).
	 Figure 2: Fe and Cu interactio s in the duodenal 
pithelium. Cu and F  can oth be absorbed into 
the enterocyte through DMT1, additionally; they 
both compete for reduction through CYBRD1. 
ATP7A is a Cu transporter that is upregulated 
during Fe deficiency. [1] 
 
Copper transporter 1 (Ctr1), trans-golgi network 
(TGN), ferroportin 1 (FPN1), hephaestin (HEPH) 
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sensitive indicator for Cu status because erythrocyte 
concentrations of SOD1 are affected by a variety of 
health and stress conditions (Danzeisen et al., 2007). 
Cp decreases during severe Cu defi ciency but is 
also an acute-phase response protein that increases 
during infl ammation and infection (Danzeisen 
et al., 2007). This may result in falsely elevated 
concentrations of Cp that could misrepresent Cu 
status. Serum Cu is tightly regulated but can also 
be elevated during infl ammation; thus, it does not 
accurately correspond to Cu status (Danzeisen et 
al., 2007). Liver Cu is the only reliable Cu status 
indicator; however, it is diffi cult to measure in 
humans without an invasive procedure (Araya et 
al., 2003). Thus, there is a critical need for a more 
sensitive and specifi c biomarker to assess Cu 
defi ciency and changes in humans.
Studies have shown that copper chaperone for 
superoxide dismutase (CCS) could be a promising 
biomarker for assessing Cu status. CCS plays an 
important role in delivering Cu to the antioxidant 
enzyme SOD1 (Culotta et al., 1997). It was found 
in rats that CCS expression is more sensitive to 
mild reductions in Cu status compared to serum 
Cu, SOD1, and Cp activity (Iskandar et al., 2005). 
CCS is elevated in the erythrocytes of Cu-defi cient 
rats and mice compared to rats and mice that are 
normal in Cu status, refl ecting a negative correlation 
between CCS and serum Cu (West & Prohaska, 
2004). Since previous animal models show that 
CCS is a promising biomarker for Cu status, we 
would like to look at this in human subjects. In this 
study, we tested CCS as a biomarker of Cu status 
in bariatric surgery patients. We hypothesized that 
CCS would respond to changes in Cu status in 
Cu-defi cient patients supplemented with copper, 
where CCS was hypothesized to decrease, and when 
altering Cu status in response to high doses of Fe 
supplementation, where CCS was hypothesized 
to increase.
OBJECTIVE
The purpose of my research is to determine whether 
concentrations of CCS in erythrocytes are associated 
with serum concentrations of Cu in patients who 
have had bariatric surgery. We will additionally 
determine whether we can observe changes in 
CCS concentrations in erythrocytes in response to 
changes in Cu status by supplementing patients with 
high doses of Cu and Fe. We expect CCS to increase 
for patients supplemented with Fe and decrease 
for patients supplemented with Cu. From this data, 
we can evaluate whether CCS would be a viable 
biomarker to test Cu status. 
METHODS
Human Subjects
The Purdue Institutional Review Board approved this 
study (#1410015305). Postcards were used to recruit 
patients who might be eligible for the study. We also 
used a recruitment service called ResNet, which is 
a database of patients who are receiving services 
through the Indiana University Health System. To 
qualify for the study, subjects must have been female, 
have had RYGB or SG bariatric surgery at least 6 
months prior to enrollment, and have been at least 
18 years of age. All subjects gave informed consent 
to participate in the study. Subjects were excluded 
if they were pregnant, had received intravenous 
(IV) Fe in the last month, or had surgical revisions 
to bariatric surgery. Men were excluded from the 
study because it is less common for men to undergo 
bariatric surgery (Buchwald & Oien, 2013). 
Screening
To enroll in the study, patients had to qualify at a 
screening visit. Patients fi lled out three-day food 
logs before coming in for their screening visits. 
At the visit, a blood draw was performed in the 
morning after the patient had undergone an 8-hour 
overnight fast. Status of Fe and Cu were measured 
by Mid America Clinical Laboratories (MACL, 
Indianapolis, IN), a commercial reference laboratory. 
Information was collected regarding demographics 
and relevant medical history during an interview. 
Height and weight were also measured at the patient 
screening visit. 
To enroll in the Fe supplementation intervention, 
patients had to have Fe defi ciency based on two or 
more of the following criteria: ferritin < 20mcg/L, 
total iron binding capacity (TIBC) > 370mcg/dL, 
soluble transferrin receptor (sTfR) > 2012mcg/L, and 
sTfR: ferritin ratio > 500 (Grant et al., 2012). In order 
to enroll in the Cu supplementation intervention, 
patients must have had Cu defi ciency at two separate 
screening visits, diagnosed by having a serum Cu 
concentration < 70mg/dL and Cp activity in plasma 
< 62.5 units/L (Gletsu-Miller et al., 2012). 
Intervention
We enrolled one patient into the Cu supplementation 
intervention and fi ve patients into the Fe 
supplementation intervention. We provided patients 
who were enrolled in the Fe supplementation 
intervention with Nature Made ferrous sulfate Fe 
supplementation at a dose of 65 mg taken three times 
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Age (years) 46 (39–49)
Sex of subject, 
female N (%) 100 %
Race/ethnicity (%) 
CA, AA, HI 94, 3, 3
Type of surgery, 
RYGB N (%) 31 (94)
Years since surgery 6.82 (3.5–10.16)
Anthropometrics
BMI (kg/m2)  30.5 (26.8–36.8)
Nutritional Status
Serum Cu (μg/dL) 109 (96–124.5)
Ferritin (μg/L) 13.75 (6.4–43.78)
CA: Caucasian; AA: African American; HI: Hispanic; BMI: 
body mass index.
Table 1. Screened patient characteristics.
a day as recommended by the bariatric surgery 
guidelines (Mechanick et al., 2013). They received 
supplementation for 8 weeks with visits at weeks 
one, two, four, and eight. We provided the patient 
who enrolled in Cu intervention Cu gluconate 
supplementation from GNC at a dose of 8 mg/day 
for 8 weeks as previously determined by Griffith and 
colleagues (2009).
At each study visit, enrolled patients went to the 
Purdue Clinical Research Center after having 
undergone an 8-hour overnight fast to have their 
blood drawn. Supplements were provided at each 
visit. Controls for this study were bariatric surgery 
patients who had undergone screening for Fe and Cu 
deficiency but were not deficient. 
Fractionation of Erythrocytes
A blood draw was obtained at all visits for both 
screened and enrolled patients. The blood was 
fractionated to separate erythrocytes, monocytes, 
and plasma as previously described (Araya et al, 
2012). Measurements of serum Cu were measured as 
described (Lassi & Prohaska, 2012). 
Western Blotting
Western blotting assays were performed using 
patients’ blood erythrocytes to test for presence of 
CCS as described by Lassi and Prohaska (2012). We 
did not regulate protein loading due to difficulty 
quantifying erythrocyte proteins. Primary antibody, 
mouse anti-rabbit polyclonal antibody against CCS, 
was obtained from West and Prohaska (2004), and 
diluted 1:500. Secondary antibody was obtained from 
Li-Cor diluted 1:10,000. Positive controls were run 
on every Western performed. We assessed CCS in 
all patients who were screened regardless of whether 
they were Cu-deficient or not. By assessing all 
patients, we were able to determine normal reference 
levels of CCS. 
STATISTICS AND DATA ANALYSIS
All data is presented as median values and 
interquartile (IQ) ranges, unless otherwise specified 
on the figure. Serum Cu and erythrocyte CCS 
correlations were performed using Spearman 
correlations for non-parametric data. Two outliers 
were removed from the data before running the 
statistical measures. A dependent sample T-test 
was performed to compare changes in the Fe 
supplemented patients’ concentrations of CCS at  
visit 1 to those of visit 4. Coefficients of variation 
(CV) for Western blots were calculated based on 
positive control samples run for both intraday 
variation and interday variation. 
RESULTS
Patient Characteristics
Table 1 shows the patient demographics and 
characteristics of all screened subjects. We screened 
32 subjects; all screened subjects were female. The 
median age of the study population was 46 years old. 
Most subjects self-identified as Caucasian (94%). 
Their BMIs ranged from 22.3 to 55.9 kg/m2. Most 
subjects underwent the RYGB surgery (94%), but one 
subject had undergone the SG.
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Figure 3. CCS and serum Cu were found not to be 
signifi cantly correlated. R = -0.092, p = 0.61.
Figure 5. Patient supplemented with Cu gluconate 
showed no change in the concentration of CCS in 
erythrocytes.
Figure 4. After 8 weeks of 8mg/day Cu gluconate 
supplementation, the patient began with 64 μg/dL of 
serum Cu and ended above a normal level at 83.4 μg/dL. 
At the end of the intervention, serum Cu concentration 
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Serum Cu were found 
not to be significantly 





ent of Copper D
efi ciency in H
um
ans 
Associations Between Erythrocyte CCS 
and Serum Cu Concentration
For the CCS assay, the intraday CV was found 
to be 16.1% and the interday CV was found to be 
18.25%. All screened patients were used to assess 
the association between erythrocye CCS and serum 
Cu. Figure 3 shows the association between the 
two measures. It was found that CCS and serum Cu 
were not signifi cantly correlated (p = 0.61).
Impact of Cu and Fe Supplementation 
on Erythrocyte CCS Concentrations
The patient supplemented with Cu had a BMI of 
22 kg/m2. The patient had a serum Cu concentration 
of 79.1 μg/dL on visit 1 and 83.4 μg/dL on visit 4. 
Figure 4 shows the serum Cu concentrations of the 
patient supplemented with Cu gluconate (8 mg/
day) for 8 weeks, where Cu status was normalized 
from baseline to visit 4. Figure 5 shows the CCS 
concentrations in erythrocytes before and after 
Cu supplementation. There was no change in CCS 
between the patient’s initial screening, baseline, and 
fi nal visit. 
Five patients were found to have Fe defi ciency. 
Their serum Cu at screening averaged to be 145.8 
μg/dL. Their ferritin concentrations increased from 
5.1 µg/L to 18.76 µg/L, visit 1 to visit 4, respectively 
(p = 0.001). All patients had increased Fe status 
at the completion of the study. Figure 6 shows the 
changes in CCS concentrations in erythrocytes for 
patients who received Fe supplementation. 
DISCUSSION
This study analyzed Cu status in normal 
and defi cient patients following Cu and Fe 
supplementation. We evaluated whether a biomarker, 
called CCS, was associated with serum Cu 
concentrations, and how CCS responds to change 
in Cu status following Fe and Cu supplementation. 
Our study found no correlation between CCS 
concentrations in erythrocytes and serum Cu. 
However, a signifi cant increase was seen in CCS 
from visit 1 to visit 4 in patients who underwent Fe 
supplementation. CCS concentrations in the patient 
who received Cu supplementation did not change at 
any point during the study. 
This study did not fi nd a signifi cant correlation 
between CCS concentrations in erythrocytes and 
serum Cu, suggesting that CCS may not be a viable 
biomarker for Cu status in human subjects. This 
result was unexpected and contradicts previous 
research performed on rats where CCS was shown 
to be an effective biomarker in representing Cu 
status (West & Prohaska, 2004). Additionally, it 
contradicts studies done on humans that showed CCS 
as a biomarker in assessing Cu toxicity (Araya et al., 
2012). As far as we know, this was the fi rst study to 
test CCS concentrations, as it relates to Cu defi ciency 
in human subjects. CCS may respond differently in 
humans than we had expected from previous studies 
conducted on rats. Because we had a high CV both 
between and within assays for our Western blots, 
it is possible that the assay itself was not reliably 
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measuring CCS concentrations in the erythrocytes 
of human subjects. Further research should be 
conducted to assess the reliability of the methods 
used for this study. 
The patient with Cu defi ciency that we provided 
with high doses of Cu gluconate supplementation, 
8 mg/day for 8 weeks, had a normalized serum Cu 
status (> 70 mg/dL) at the conclusion of the study. 
For this patient, 8 mg/day was a suffi cient amount 
of Cu supplementation to replete her Cu status by 
measurement of her serum Cu. The CCS values for 
this patient did not appear to change from visit 1 to 
visit 4. It was surprising to only fi nd one patient with 
Cu defi ciency since our lab previously saw much 
higher incidence of Cu defi ciency in the bariatric 
surgery population (Gletsu-Miller et al., 2012). 
Different geographical locations or a difference 
in diet may be reasons why we are seeing less 
incidence of Cu defi ciency. Since Cu is affected by 
infl ammation, high BMI in some of the patients may 
also be a factor that is affecting Cu status (Danzeisen 
et al., 2007). We suspect that dietary Cu is also 
associated with Cu status, but since we found only 
one patient with Cu defi ciency, this remains to be 
determined. There is no evidence to suggest that 
blood loss through menstruation has an effect on Cu 
status. More patients with Cu defi ciency would be 
needed to determine whether this supplementation 
treatment is suffi cient to replete Cu status in patients 
who are Cu-defi cient, and to evaluate whether 
erythrocyte CCS responds to changes in Cu status 
following high-dose Cu supplementation. 
In the other intervention, we had fi ve patients who 
were enrolled to receive Fe supplementation. As we had 
expected, all the patients had a normalized Fe status 
at the conclusion of the study. A previous study in our 
lab analyzed dietary recall data of the subjects and 
showed that dietary Fe was associated with Fe status 
independent of the level of obesity, meaning patients 
who consumed less dietary Fe were more likely to be 
defi cient (Mischler et al., 2015). Blood losses through 
menstruation or gastrointestinal problems are other 
areas that may affect Fe status in patients. The Fe 
supplement successfully normalized defi cient patients. 
There was a consistent increase in CCS from visit 
1 to visit 4 in patients who were supplemented with 
Fe. Previous studies have shown that Cu status is 
low when Fe is high in animal models that consume 
high dietary Fe, and this study saw a similar trend 
in terms of erythrocyte CCS indicator of Cu status 
(Gulec & Collins, 2014; Jung-Heun Ha et al., 2016). 
After receiving high doses of supplementary Fe for 
8 weeks, patients had a signifi cant increase in CCS. 
This implies that there is an interaction between Fe 
and CCS. Because no correlation was found between 
CCS and serum Cu, we cannot determine if a change in 
Cu status in these patients is a potential reason for the 
change in CCS.
The present study is limited by its low statistical power, 
having only one patient supplemented with Cu and fi ve 
patients supplemented with Fe. However, as the study 
is ongoing, the sample size will continue to increase. 
The study also only recruited females and all of the 
study subjects were Caucasian, so the study may not 
be generalizable to men or other races.  In addition, we 
do not know what the serum Cu concentrations are for 
those enrolled in the Fe supplementation study. We did 
not record where patients were in their menstrual cycle 
at the time blood draws were taken. This would have an 
effect on Fe status, but there is no evidence to suggest 
that the menstrual cycle affects Cu status. We are 
actively working to obtain those values to explore how 
Figure 6: CCS between visits 1 and visit 4 significantly increase across all Fe supplemented 
patients (p=0.046). A) The image of the western blot for Fe supplemented patients. GAPDH 
was used as the control across the patients. B) All patients’ CCS concentrations in 
erythrocytes increased after undergoing Fe supplementation. Mean [SEM] CCS for visit 1 
was 0.958 [0.164] which increased to 1.247 [0.154] at visit 4.  
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serum Cu may have changed compared to erythrocyte 
CCS in reaction to high doses of Fe supplementation.
While this study did not fi nd a signifi cant association 
between CCS in erythrocytes and serum Cu in human 
subjects, we did fi nd a signifi cant increase in CCS from 
visit 1 to visit 4 in patients who received high doses of 
Fe supplementation. We were also able to replete the Cu 
status of the Cu-defi cient patient who took high doses 
of Cu supplementation, though the patient’s erythrocyte 
CCS concentrations were unchanged. We will continue 
to screen for patients who have Cu or Fe defi ciency and 
treat them with high doses or oral supplementation. 
We will also continue to explore associations between 
CCS in erythrocytes and serum Cu in patients who 
have undergone bariatric surgery. Future studies should 
explore dietary records collected and how that relates to 
Cu status. Because obesity is an infl ammatory disease, 
future studies should investigate whether BMI and 
body weight of patients affects Cu status, since serum 
Cu is elevated during infl ammation (Danzeisen et al., 
2007). Future studies should also explore how age of 
patients may affect Cu status.
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